Cargando…

Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease

BACKGROUND: Glycoprotein 2 (GP2) was discovered as the major autoantigen of Crohn’s disease (CD)-specific pancreatic autoantibodies (PAB). We investigated anti-GP2 IgA and IgG antibodies as novel serological parameters in CD and assessed their association with distinct disease phenotypes. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogdanos, Dimitrios P, Roggenbuck, Dirk, Reinhold, Dirk, Wex, Thomas, Pavlidis, Polychronis, von Arnim, Ulrike, Malfertheiner, Peter, Forbes, Alastair, Conrad, Karsten, Laass, Martin W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3449192/
https://www.ncbi.nlm.nih.gov/pubmed/22866900
http://dx.doi.org/10.1186/1471-230X-12-102
_version_ 1782244322503032832
author Bogdanos, Dimitrios P
Roggenbuck, Dirk
Reinhold, Dirk
Wex, Thomas
Pavlidis, Polychronis
von Arnim, Ulrike
Malfertheiner, Peter
Forbes, Alastair
Conrad, Karsten
Laass, Martin W
author_facet Bogdanos, Dimitrios P
Roggenbuck, Dirk
Reinhold, Dirk
Wex, Thomas
Pavlidis, Polychronis
von Arnim, Ulrike
Malfertheiner, Peter
Forbes, Alastair
Conrad, Karsten
Laass, Martin W
author_sort Bogdanos, Dimitrios P
collection PubMed
description BACKGROUND: Glycoprotein 2 (GP2) was discovered as the major autoantigen of Crohn’s disease (CD)-specific pancreatic autoantibodies (PAB). We investigated anti-GP2 IgA and IgG antibodies as novel serological parameters in CD and assessed their association with distinct disease phenotypes. METHODS: Anti-GP2 and anti-Saccharomyces cerevisiae (ASCA) IgA and IgG were detected by ELISA employing recombinant human GP2 and phosphopeptidomannan, respectively and PAB by indirect immunofluorescence (IIF) in 271 sera, 169 with CD and 102 with ulcerative colitis (UC). As healthy controls 160 adult blood donors and 65 children were included. RESULTS: Anti-GP2 IgG and/or IgA were more prevalent in CD (51/169, 30.2%) than in UC (9/102, 8.9%) patients and in controls (9/225, 4%) (p < 0.001 respectively). ASCA IgG and/or IgA were present in 60/169 (35.5%) in CD and in 7/102 (6.9%) in UC patients (p < 0.001). CD patients with ileocolonic location (L3) showed a significantly higher prevalence of anti-GP2 and ASCA IgA and/or IgG (40/113 and 48/113, respectively; p < 0.05 for both comparisons), whereas CD patients with colonic location (L2) revealed a significantly diminished prevalence for these autoantibody specificities (2/32 and 5/32, respectively, p < 0.05 for both). Anti-GP2 IgG were significantly more prevalent in CD patients with stricturing behaviour (B2) and perianal disease (7/11, p < 0.02) and less prevalent in those with penetrating behaviour (B3) and perianal disease (4/31, p < 0.05). The occurrence of anti-GP2 IgA and/or IgG was significantly more prevalent in CD patients with age at diagnosis of ≤16 years (16/31, p < 0.009). Prevalence of one or more anti-GP2 or ASCA IgA and/or IgG was significantly higher in L3, B2, and A1 and lower in L2 (68/113, 27/41, 23/31, 6/32; p < 0.04, respectively). CONCLUSIONS: Anti-GP2 IgG and IgA, constituting novel CD specific autoantibodies, appear to be associated with distinct disease phenotypes identifying patients at a younger age, with ileocolonic location, and stricturing behaviour with perianal disease.
format Online
Article
Text
id pubmed-3449192
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34491922012-09-24 Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease Bogdanos, Dimitrios P Roggenbuck, Dirk Reinhold, Dirk Wex, Thomas Pavlidis, Polychronis von Arnim, Ulrike Malfertheiner, Peter Forbes, Alastair Conrad, Karsten Laass, Martin W BMC Gastroenterol Research Article BACKGROUND: Glycoprotein 2 (GP2) was discovered as the major autoantigen of Crohn’s disease (CD)-specific pancreatic autoantibodies (PAB). We investigated anti-GP2 IgA and IgG antibodies as novel serological parameters in CD and assessed their association with distinct disease phenotypes. METHODS: Anti-GP2 and anti-Saccharomyces cerevisiae (ASCA) IgA and IgG were detected by ELISA employing recombinant human GP2 and phosphopeptidomannan, respectively and PAB by indirect immunofluorescence (IIF) in 271 sera, 169 with CD and 102 with ulcerative colitis (UC). As healthy controls 160 adult blood donors and 65 children were included. RESULTS: Anti-GP2 IgG and/or IgA were more prevalent in CD (51/169, 30.2%) than in UC (9/102, 8.9%) patients and in controls (9/225, 4%) (p < 0.001 respectively). ASCA IgG and/or IgA were present in 60/169 (35.5%) in CD and in 7/102 (6.9%) in UC patients (p < 0.001). CD patients with ileocolonic location (L3) showed a significantly higher prevalence of anti-GP2 and ASCA IgA and/or IgG (40/113 and 48/113, respectively; p < 0.05 for both comparisons), whereas CD patients with colonic location (L2) revealed a significantly diminished prevalence for these autoantibody specificities (2/32 and 5/32, respectively, p < 0.05 for both). Anti-GP2 IgG were significantly more prevalent in CD patients with stricturing behaviour (B2) and perianal disease (7/11, p < 0.02) and less prevalent in those with penetrating behaviour (B3) and perianal disease (4/31, p < 0.05). The occurrence of anti-GP2 IgA and/or IgG was significantly more prevalent in CD patients with age at diagnosis of ≤16 years (16/31, p < 0.009). Prevalence of one or more anti-GP2 or ASCA IgA and/or IgG was significantly higher in L3, B2, and A1 and lower in L2 (68/113, 27/41, 23/31, 6/32; p < 0.04, respectively). CONCLUSIONS: Anti-GP2 IgG and IgA, constituting novel CD specific autoantibodies, appear to be associated with distinct disease phenotypes identifying patients at a younger age, with ileocolonic location, and stricturing behaviour with perianal disease. BioMed Central 2012-08-06 /pmc/articles/PMC3449192/ /pubmed/22866900 http://dx.doi.org/10.1186/1471-230X-12-102 Text en Copyright ©2012 Bogdanos et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bogdanos, Dimitrios P
Roggenbuck, Dirk
Reinhold, Dirk
Wex, Thomas
Pavlidis, Polychronis
von Arnim, Ulrike
Malfertheiner, Peter
Forbes, Alastair
Conrad, Karsten
Laass, Martin W
Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease
title Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease
title_full Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease
title_fullStr Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease
title_full_unstemmed Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease
title_short Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease
title_sort pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with crohn’s disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3449192/
https://www.ncbi.nlm.nih.gov/pubmed/22866900
http://dx.doi.org/10.1186/1471-230X-12-102
work_keys_str_mv AT bogdanosdimitriosp pancreaticspecificautoantibodiestoglycoprotein2mirrordiseaselocationandbehaviourinyoungerpatientswithcrohnsdisease
AT roggenbuckdirk pancreaticspecificautoantibodiestoglycoprotein2mirrordiseaselocationandbehaviourinyoungerpatientswithcrohnsdisease
AT reinholddirk pancreaticspecificautoantibodiestoglycoprotein2mirrordiseaselocationandbehaviourinyoungerpatientswithcrohnsdisease
AT wexthomas pancreaticspecificautoantibodiestoglycoprotein2mirrordiseaselocationandbehaviourinyoungerpatientswithcrohnsdisease
AT pavlidispolychronis pancreaticspecificautoantibodiestoglycoprotein2mirrordiseaselocationandbehaviourinyoungerpatientswithcrohnsdisease
AT vonarnimulrike pancreaticspecificautoantibodiestoglycoprotein2mirrordiseaselocationandbehaviourinyoungerpatientswithcrohnsdisease
AT malfertheinerpeter pancreaticspecificautoantibodiestoglycoprotein2mirrordiseaselocationandbehaviourinyoungerpatientswithcrohnsdisease
AT forbesalastair pancreaticspecificautoantibodiestoglycoprotein2mirrordiseaselocationandbehaviourinyoungerpatientswithcrohnsdisease
AT conradkarsten pancreaticspecificautoantibodiestoglycoprotein2mirrordiseaselocationandbehaviourinyoungerpatientswithcrohnsdisease
AT laassmartinw pancreaticspecificautoantibodiestoglycoprotein2mirrordiseaselocationandbehaviourinyoungerpatientswithcrohnsdisease